Introduction to the Single Ventricle Reconstruction trial

Emile Bacha, MD,^a and Pedro del Nido, MD^b

The Single Ventricle Reconstruction (SVR) trial, sponsored by the National Heart, Lung, and Blood Institute and carried out by 15 clinical centers, randomized 549 neonates and showed that transplantation-free survival at 14 months was significantly higher overall with the right ventricle-to-pulmonary artery shunt (RVPAS) compared with the modified Blalock-Taussig shunt (MBTS).¹ Any surgical procedure that does not exceed 65% survival at 1 year deserves to be studied and scrutinized relentlessly. Although the primary outcome was clear when considering the entire study cohort, many questions remained regarding the impact of comorbidities; intraoperative, postoperative, and interstage management strategies on morbidity and mortality; and the mechanisms of death throughout the study period.

The compilation of 5 follow-up articles²⁻⁶ represents secondary analyses of the SVR trial, and their main value is that they provide a more detailed analysis of areas that could not be covered in the *New England Journal of Medicine* article.¹ The SVR trial fortunately included enough study patients, and collected a vast amount of data, to permit analysis of the interaction of risk factors with shunt type²; the risk factors of hospital morbidity and mortality after the Norwood³; the impact of shunt type and other risk factors on interstage mortality⁴; the cause, timing, and location of death after the Norwood⁵; as well as a descriptive study on practice variation in perioperative care found across centers.⁶

Some of the findings confirm the findings of previous retrospective studies or database extraction studies, such as the impact of center/surgeon volume, the major and independent role of extracardiac anomalies, genetic syndromes, low gestational age and birth weight, smaller ascending aorta, obstructed pulmonary venous return, and lower socioeconomic status play on outcomes. Patients with aortic stenosis/mitral stenosis did better than any other subgroup, presumably because of the presence of antegrade aortic flow, and patients with aortic atresia/mitral stenosis did not exhibit a higher mortality, although the presence or

absence of coronary fistulae was not documented. Another novel and noteworthy finding of these secondary analyses include the observation that term infants with aortic atresia (51% of the cohort) did considerably better with an RVPAS at 12 months (mortality one third that of a similar patient with MBTS), which is significant and lines up neatly with a physiologic explanation of superior diastolic coronary flow and lack of coronary steal in RVPAS patients. Conversely, in 4% of the cohort (preterm infants with a patent aortic valve), the MBTS was superior. No clear explanation exists for this finding, and one could speculate that the ventriculotomy is less well tolerated in preterm infants. This was a much smaller group of patients and thus statistical inferences are more suspect. For term infants with a patent aortic valve and for preterm infants with aortic atresia, no clear difference between RVPAS and MBTS was seen. This may be because the former group does well with either shunt type and that, in the latter group, the benefit of the RVPAS on coronary flow may be offset by the downsides of a ventriculotomy.

Open sternum was identified as a significant risk factor independent of the center's strategy (elective vs routine sternal closure). However, the study did show that, in selected patients, primary sternal closure is a safe alternative. These types of associations, however, are always difficult to interpret because this "outcome variable" is dependent on the surgeon's decision at the end of the procedure and may reflect patient instability or even a concern with technical aspects of the surgery that are not captured by the usual data-gathering process.

Other notable findings were that interstage mortality was significantly better for the RVPAS compared with MBTS, unless atrioventricular valve regurgitation was moderate to severe, in which case this overshadowed the shunt type and interstage mortality was similar. Not surprisingly, most deaths occurred during initial hospitalization. The nonspecific determination of "cardiovascular death" was the most common cause, a sure way to frustrate readers who will long to get some clues as to what often remains an unexplained phenomenon: the sudden unexplained death after Norwood. It is important to note that whatever autopsy data were available were in large part nonrevelatory.

In conclusion, these combined studies point to the RVPAS as being beneficial in term infants with aortic atresia and as being associated with lower interstage mortality in general. For term patients with aortic stenosis/mitral stenosis, either shunt is associated with better survival. These studies represent significant new knowledge. Sadly, improved survival after Norwood, let alone quality of life,

From the Division of Cardiac Surgery,^a Columbia University, and New York-Presbyterian-Morgan Stanley Children's Hospital, New York, NY; and Department of Cardiac Surgery,^b Children's Hospital—Boston, and Harvard Medical School, Boston, Mass.

Disclosures: Authors have nothing to disclose with regard to commercial support. Address for reprints: Emile Bacha, MD, New York-Presbyterian-Morgan Stanley Children's Hospital, 3959 Broadway, CHN-274, New York, NY 10032 (E-mail: eb2709@columbia.edu).

J Thorac Cardiovasc Surg 2012;144:880-1
0022-5223/\$36.00

Copyright © 2012 by The American Association for Thoracic Surgery
<http://dx.doi.org/10.1016/j.jtcvs.2012.08.031>

remains an elusive goal that we as a profession are reaching only incrementally.

References

1. Ohye RG, Sleeper LA, Mahony L, Newburger JW, Pearson GD, Lu M, et al. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. *N Engl J Med*. 2010;362:1980-92.
2. Tweddell JS, Sleeper LA, Ohye RG, Williams IA, Mahony L, Pizarro C, et al. Intermediate-term mortality and cardiac transplantation in infants with single-ventricle lesions: Risk factors and their interaction with shunt type. *J Thorac Cardiovasc Surg*. 2012;144:152-9.e2.
3. Tabbutt S, Ghanayem N, Ravishankar C, Sleeper LA, Cooper DS, Frank DU, et al. Risk factors for hospital morbidity and mortality after the Norwood procedure: a report from the Pediatric Heart Network Single Ventricle Reconstruction trial. *J Thorac Cardiovasc Surg*. 2012;144:882-95.
4. Ghanayem NS, Allen KR, Tabbutt S, Atz AM, Clabby ML, Cooper DS, et al. Interstage mortality after the Norwood procedure: Results of the multicenter Single Ventricle Reconstruction trial. *J Thorac Cardiovasc Surg*. 2012;144:896-906.
5. Ohye RG, Schonbeck JV, Eghtesday P, Laussen PC, Pizarro C, Schrader P, Frank DU. Cause, timing and location of death in the single ventricle reconstruction trial. *J Thorac Cardiovasc Surg*. 2012;144:907-14.
6. Pasquali SK, Ohye RG, Lu M, Kaltman J, Caldarone CA, Pizarro C, et al. Variation in perioperative care across centers for infants undergoing the Norwood procedure. *J Thorac Cardiovasc Surg*. 2012;144:915-21.